Myocyte Changes in Heart Failure

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 1-6

  Savinova, Olga V ^a   Gerdes, A Martin ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cardiac hypertrophy; Cardiomyocyte; Heart failure; Structural remodeling

Indexed keywords

ACTIN; ALPHA TROPOMYOSIN; ANGIOTENSIN II; DYSTROPHIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; PHENYLEPHRINE; PIOGLITAZONE; TROPONIN I; TROPONIN T;

CARDIOVASCULAR RISK; CELL GROWTH; CELL HYPERPLASIA; CELL SHAPE; CELL STRUCTURE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; GROWTH REGULATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MITRAL ANNULOPLASTY; REVIEW;

ANIMALS; DISEASE PROGRESSION; HEART FAILURE; HEART VENTRICLES; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; VENTRICULAR REMODELING;

EID: 82955213054     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.004     Document Type: Review

References (44)

1. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5(2):167-173.
2. Kannel W.B., Ho K., Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994, 72(Suppl 2):S3-S9.
3. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):e391-e479.
4. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005, 46(6):e1-e82.
5. Gerdes A.M. Cardiac myocyte remodeling in hypertrophy and progression to failure. J Card Fail 2002, 8(Suppl 6):S264-S268.
6. Gerdes A.M., Moore J.A., Hines J.M., et al. Regional differences in myocyte size in normal rat heart. Anat Rec 1986, 215(4):420-426.
7. Gerdes A.M., Capasso J.M. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 1995, 27(3):849-856.
8. Gerdes A.M., Kellerman S.E., Moore J.A., et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 1992, 86(2):426-430.
9. Zafeiridis A., Jeevanandam V., Houser S.R., et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98(7):656-662.
10. Kajstura J., Zhang X., Liu Y., et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995, 92(8):2306-2317.
11. Kramer C.M., Rogers W.J., Park C.S., et al. Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. J Mol Cell Cardiol 1998, 30(9):1773-1778.
12. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7(2):79-108.
13. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975, 56(1):56-64.
14. Thomas T.A., Kuzman J.A., Anderson B.E., et al. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol 2005, 288(5):H2118-H2122.
15. Russell B., Motlagh D., Ashley W.W. Form follows function: how muscle shape is regulated by work. J Appl Physiol 2000, 88(3):1127-1132.
16. Goktepe S., Abilez O.J., Parker K.K., et al. A multiscale model for eccentric and concentric cardiac growth through sarcomerogenesis. J Theor Biol 2010, 265(3):433-442.
17. Inoue T., Sakai Y., Morooka S., et al. Coronary flow reserve in patients with dilated cardiomyopathy. Am Heart J 1993, 125(1):93-98.
18. Bowles N.E., Bowles K.R., Towbin J.A. The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000, 25(3):168-175.
19. Geisterfer-Lowrance A.A., Kass S., Tanigawa G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990, 62(5):999-1006.
20. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77(5):701-712.
21. Bonne G., Carrier L., Bercovici J., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995, 11(4):438-440.
22. Watkins H., Conner D., Thierfelder L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995, 11(4):434-437.
23. Poetter K., Jiang H., Hassanzadeh S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996, 13(1):63-69.
24. Kimura A., Harada H., Park J.E., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997, 16(4):379-382.
25. Mogensen J., Klausen I.C., Pedersen A.K., et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103(10):R39-R43.
26. Towbin J.A., Hejtmancik J.F., Brink P., et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993, 87(6):1854-1865.
27. Ortiz-Lopez R., Li H., Su J., et al. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation 1997, 95(10):2434-2440.
28. Li D., Tapscoft T., Gonzalez O., et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999, 100(5):461-464.
29. Maeda M., Holder E., Lowes B., et al. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 1997, 95(1):17-20.
30. Olson T.M., Michels V.V., Thibodeau S.N., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998, 280(5364):750-752.
31. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122(25):2727-2735.
32. Russell B., Curtis M.W., Koshman Y.E., et al. Mechanical stress-induced sarcomere assembly for cardiac muscle growth in length and width. J Mol Cell Cardiol 2010, 48(5):817-823.
33. Brancaccio M., Fratta L., Notte A., et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 2003, 9(1):68-75.
34. Sbroggio M., Ferretti R., Percivalle E., et al. The mammalian CHORD-containing protein melusin is a stress response protein interacting with Hsp90 and Sgt1. FEBS Lett 2008, 582(13):1788-1794.
35. Hinrichs S., Heger J., Schreckenberg R., et al. Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}. Cardiovasc Res 2011, 89(2):344-352.
36. Kehat I., Davis J., Tiburcy M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011, 108(2):176-183.
37. Hellawell J.L., Margulies K.B. Myocardial reverse remodeling. Cardiovasc Ther 2010, [Epub ahead of print].
38. Takeda K., Taniguchi K., Shudo Y., et al. Mechanism of beneficial effects of restrictive mitral annuloplasty in patients with dilated cardiomyopathy and functional mitral regurgitation. Circulation 2010, 122(Suppl 11):S3-S9.
39. Stulak J.M., Suri R.M., Dearani J.A., et al. Does early surgical intervention improve left ventricular mass regression after mitral valve repair for leaflet prolapse?. J Thorac Cardiovasc Surg 2011, 141(1):122-129.
40. Solomon S.D., Foster E., Bourgoun M., et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 2010, 122(10):985-992.
41. Birks E.J. Myocardial recovery in patients with chronic heart failure: is it real?. J Card Surg 2010, 25(4):472-477.
42. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355(18):1873-1884.
43. Tamura T., Said S., Harris J., et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 2000, 102(2):253-259.
44. Gerdes A.M., Clark L.C., Capasso J.M. Regression of cardiac hypertrophy after closing an aortocaval fistula in rats. Am J Physiol 1995, 268(6 Pt 2):H2345-H2351.